Table 1.
Clinical Characteristics
| Variables | N | % |
|---|---|---|
| All | 203 | 100.0 |
| Age (y) | ||
| ≤ 50 | 47 | 23.2 |
| > 50 | 156 | 76.8 |
| T-stage | ||
| 1 | 137 | 67.5 |
| > 1 | 66 | 32.5 |
| N-stage | ||
| 0 | 120 | 59.4 |
| > 1 | 82 | 40.6 |
| Grade | ||
| 1 and 2 | 125 | 62.8 |
| 3 | 74 | 37.2 |
| Histology | ||
| IDC | 175 | 86.2 |
| Others | 28 | 13.8 |
| Hormone receptor status* | ||
| Negative | 33 | 16.5 |
| Positive | 167 | 83.5 |
| HER2 status | ||
| Negative | 171 | 84.2 |
| Amplified | 32 | 15.8 |
| Ki-67† | ||
| Low | 116 | 57.4 |
| High | 86 | 42.6 |
| Tumor multifocality | ||
| Negative | 180 | 89.1 |
| Positive | 22 | 10.9 |
| Tumor subtypes | ||
| Luminal A like | 80 | 40.2 |
| Luminal B like HER2 − | 62 | 31.2 |
| Luminal B like HER2 + | 27 | 13.5 |
| HER2 + nonluminal | 5 | 2.5 |
| Triple negative | 25 | 12.6 |
| CTC EP | ||
| Negative | 168 | 90.8 |
| Positive | 17 | 9.2 |
| CTC EMT | ||
| Negative | 160 | 84.2 |
| Positive | 30 | 15.8 |
| CTC any | ||
| Negative | 148 | 77.1 |
| Positive | 44 | 22.9 |
*
Negative for both or positive for either with cutoff 10%.
†
Cutoff 20%.